Why is Summit stock in selloff after late-stage trial data for lead asset?
Source: SeekingAlpha
2025-05-30 14:47:46 ET
More on Summit Therapeutics
- Summit Therapeutics: Critical NSCLC Study Readout Jeopardizes Ivonesimab Approval
- Summit Therapeutics Inc. (SMMT) Q1 2025 Earnings Call Transcript
- Summit Therapeutics: New Ivonescimab Data Raise Concerns
- Summit claims late-stage trial win for lung cancer therapy
- SA Asks: What are the best oncology stocks right now?
Read the full article on Seeking Alpha
For further details see:
Why is Summit stock in selloff after late-stage trial data for lead asset?
Akeso
NASDAQ: AKESF
AKESF Trading
-0.44% G/L:
$16.925 Last:
2,828 Volume:
$17 Open:
